Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Andritz AG stock logo
ADRZY
Andritz
$14.45
+1.7%
$13.46
$9.35
$14.62
$7.51B0.866,968 shs313 shs
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
$45.02
$42.32
$33.94
$45.40
$7.25B0.278,687 shsN/A
Fuchs SE stock logo
FUPBY
Fuchs
$14.10
-0.4%
$12.47
$9.98
$14.20
$7.84B0.95,704 shs3,065 shs
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$104.49
$90.04
$34.26
$105.60
$1.88B0.221,266 shs2,500 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Andritz AG stock logo
ADRZY
Andritz
+1.07%+0.42%+1.07%+12.11%+17.78%
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
0.00%-0.85%+4.67%+19.47%+21.54%
Fuchs SE stock logo
FUPBY
Fuchs
-0.35%+2.69%+11.95%+8.18%+16.76%
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.00%+0.86%+29.15%+2.36%+235.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Andritz AG stock logo
ADRZY
Andritz
N/AN/AN/AN/AN/AN/AN/AN/A
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
N/AN/AN/AN/AN/AN/AN/AN/A
Fuchs SE stock logo
FUPBY
Fuchs
N/AN/AN/AN/AN/AN/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.3257 of 5 stars
0.03.00.00.02.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Andritz AG stock logo
ADRZY
Andritz
2.00
HoldN/AN/A
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
2.00
HoldN/AN/A
Fuchs SE stock logo
FUPBY
Fuchs
1.00
SellN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest PHMMF, FUPBY, ADRZY, and CHBAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2025
Andritz AG stock logo
ADRZY
Andritz
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Outperform
3/26/2025
Fuchs SE stock logo
FUPBY
Fuchs
DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Andritz AG stock logo
ADRZY
Andritz
$9.37B0.80$1.88 per share7.69$4.49 per share3.22
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
$2.15B3.37$4.20 per share10.72$53.63 per share0.84
Fuchs SE stock logo
FUPBY
Fuchs
$3.83B2.05$0.85 per share16.63$3.51 per share4.02
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$171.15M11.00$0.45 per share231.27$11.62 per share8.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Andritz AG stock logo
ADRZY
Andritz
$552.19M$1.0413.2613.26N/A5.90%23.10%6.10%7/31/2025 (Estimated)
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
$432.52M$3.4114.62N/A19.54%5.75%0.30%7/31/2025 (Estimated)
Fuchs SE stock logo
FUPBY
Fuchs
$306.29M$0.6322.7421.042.188.52%16.61%12.17%7/29/2025 (Estimated)
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$1.23MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)

Latest PHMMF, FUPBY, ADRZY, and CHBAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q4 2025
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
$0.7550$0.93+$0.1750$0.91$52.55 billion$686.60 million
4/30/2025Q1 2025
Andritz AG stock logo
ADRZY
Andritz
$0.2191$0.19-$0.0291$0.19$1.80 billion$2.00 billion
4/30/2025Q1 2025
Fuchs SE stock logo
FUPBY
Fuchs
$0.1710$0.16-$0.0110$0.16$945.00 million$1.05 billion
3/21/2025Q4 2024
Fuchs SE stock logo
FUPBY
Fuchs
$0.1397$0.14+$0.0003$0.14$927.59 million$930.07 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Andritz AG stock logo
ADRZY
Andritz
$0.342.35%N/A32.69%N/A
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
$0.591.31%N/A17.30%N/A
Fuchs SE stock logo
FUPBY
Fuchs
$0.171.21%N/A26.98%N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/A

Latest PHMMF, FUPBY, ADRZY, and CHBAY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/3/2025
Fuchs SE stock logo
FUPBY
Fuchs
$0.17321.36%5/9/20255/12/20255/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Andritz AG stock logo
ADRZY
Andritz
0.24
1.16
0.89
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
1.49
0.95
0.95
Fuchs SE stock logo
FUPBY
Fuchs
0.02
2.08
1.19
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.14
2.55
2.01

Institutional Ownership

CompanyInstitutional Ownership
Andritz AG stock logo
ADRZY
Andritz
N/A
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
N/A
Fuchs SE stock logo
FUPBY
Fuchs
N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/A

Insider Ownership

CompanyInsider Ownership
Andritz AG stock logo
ADRZY
Andritz
N/A
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
N/A
Fuchs SE stock logo
FUPBY
Fuchs
N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
1.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Andritz AG stock logo
ADRZY
Andritz
29,717520.00 millionN/ANot Optionable
The Chiba Bank, Ltd. stock logo
CHBAY
Chiba Bank
4,142161.10 millionN/ANot Optionable
Fuchs SE stock logo
FUPBY
Fuchs
6,272556.00 millionN/ANot Optionable
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
50918.01 millionN/ANot Optionable

Recent News About These Companies

Exploring High Growth Tech Stocks in Europe April 2025
High Growth Tech Leads These 3 Top Stocks with Potential
Insider-Led Growth Stocks To Watch In December 2024
Pharma Mar S.A. Reduces Share Capital by Canceling Shares
Pharma Mar Achieves Legal Win in Aplidin Case

Media Sentiment Over Time

Andritz stock logo

Andritz OTCMKTS:ADRZY

$14.45 +0.24 (+1.69%)
As of 03:47 PM Eastern

Andritz AG provides plants, equipment, and services for pulp and paper industry, metalworking and steel industries, hydropower stations, and solid/liquid separation in the municipal and industrial sectors in Europe, North America, South America, China, Asia, and internationally. It operates through four segments: Pulp & Paper, Metals, Hydro, and Separation. The Pulp & Paper segment supplies technology, automation, and service solutions to produce pulp, paper, board, and tissue; boilers for power generation; flue gas cleaning systems; nonwovens technologies; panelboard production systems; and recycling, shredding, and energy solutions for various waste materials. The Metals segment provides technologies, plants, and digital solutions, including automation and software solutions, and process know-how and services; and solutions for the production and processing of flat products for welding systems and industrial furnaces, as well as services for the metals processing industry. The Hydro segment supplies electromechanical equipment and services for hydropower plants; offers plant diagnosis, refurbishment, modernization, and upgradation of existing hydropower plants; and pumps for irrigation, water supply, and flood control, as well as turbo generators. The Separation segment offers mechanical and thermal technologies, as well as services and related automation solutions for solid/liquid separation to serve chemical, environmental, food, mining, and minerals industries; and technologies and services to produce animal feed and biomass pellets. The company was founded in 1852 and is headquartered in Graz, Austria.

Chiba Bank stock logo

Chiba Bank OTCMKTS:CHBAY

$45.02 0.00 (0.00%)
As of 06/11/2025

The Chiba Bank, Ltd., together with its subsidiaries, provides banking products and services in Japan and internationally. The company offers various deposit products, including savings, time deposits, currency deposits, investment trusts, bonds, and pensions; loans, which include mortgages, renovation loans, photovoltaic, vehicle, education, and other loan products; and insurance products, such as annuity, life, medical, student, death, and travel insurance. It also offers debit and credit cards, as well as internet banking services. In addition, the company engages in securities, investment management and advisory, software development, commissioned computation tasks, research and investigation of IT and financial technologies, leasing, operation, and management of investment funds, mergers and acquisition advisory, credit guarantee businesses, management and collection of claims businesses. Further, it provides loan guarantees and fee collection services; accounting, general administration entrustment, and temporary staff services; and is involved in outsourcing of operational business. Additionally, it rents and maintains office buildings and welfare facilities; provides research, survey, and consulting services; purchases and sells supplies and consumer goods; and engages in renewable energy generation. The company serves individuals and corporations. The Chiba Bank, Ltd. was incorporated in 1943 and is headquartered in Chiba City, Japan.

Fuchs stock logo

Fuchs OTCMKTS:FUPBY

$14.10 -0.05 (-0.35%)
As of 03:46 PM Eastern

Fuchs SE develops, produces, and sells lubricants and related specialties in Europe, the Middle East, Africa, the Asia Pacific, and North and South America. The company offers automotive lubricants, such as biodegradable lubricants, central and mobile hydraulic oils, dry coatings, engine and gear oils, motorcycle/two wheelers, and service fluids, as well as various oils for agriculture sector. It also provides industrial lubricants, including chain lubricants, dry coatings, gear and hydraulic oils, machine oils, open gear lubricants, rapidly biodegradable lubricants, compressor and refrigeration oils, release agents, slideways oils, fluids and industrial oils, textile machine oils, and turbine oils. In addition, the company offers lubricating greases comprising assembly pastes, biodegradable greases, food grade greases, multi-purpose/long-life greases, pastes for extreme temperatures, perfluorinated pastes, and wheel bearing greases, as well as gear boxes, and greases for central lubricating system, extreme temperature, machine tools, plain and roller bearings, rail vehicles, spray cans or rattle cans, and solid lubricants. Further, it provides metal processing lubricants consisting of cleaners, corrosion preventives, cutting and grinding, forming lubricants, and quenching oils; and special application lubricants for application equipment, chain lubrication, dry coatings, food and beverage, gears, sugar processing, railway traffic, plain and roller bearings, glass manufacturing process, hot forming, maintenance, open gears, pastes, release agents, other specialties, special greases, and wind power plants. Additionally, the company offers open gear and surface coating services. The company was formerly known as Fuchs Petrolub SE and changed its name to Fuchs SE in July 2023. Fuchs SE was founded in 1931 and is headquartered in Mannheim, Germany.

Pharma Mar stock logo

Pharma Mar OTCMKTS:PHMMF

$104.49 0.00 (0.00%)
As of 06/11/2025

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.